Viatris, formed from Mylan and Pfizer's Established Brands, has faced stock price volatility since its inception in 2020. I rated Viatris a "Buy" last October, based on management's completion of ...

Shares of Viatris Inc. VTRS advanced 1.72% to $11.25 Friday, on what proved to be an all-around rough trading session for the ...

The firm believes that for Viatris to see multiple expansion over time, it will require clinical and regulatory success with its "innovative" brand assets. This outlook follows the company's ...

Shares of Viatris Inc. VTRS advanced 1.19% to $11.06 Thursday, on what proved to be an all-around dismal trading session for ...